Information was received from a healthcare provider (hcp) via a clinical study regarding a patient receiving bupivacaine (30.0 mg/ml at 13.503 mg/day), clonidine (300.0 mcg/ml at 135.03 mcg/day), and morphine (5.0 mg/ml at 2.2505 mg/day) via an implantable infusion pump.The indication for use was noted as non-malignant pain.It was reported the patient had lightheadedness, low blood pressure, and upper extremity and abdominal numbness following ptm activations on (b)(6) 2017.The clinical diagnosis was it medication side effects following ptm activations and it medication side effects with or without side effects.The pump was reprogrammed and the continuous rate was decreased.On (b)(6) 2017, the patient reported feeling lightheaded following ptm activations and requested a change to the concentration of medications.The patient was refilled with a new concentration of medications and opioid was rotated to allow for decreased clonidine and bupivacaine on (b)(6) 2017.It was noted the patient's pump was interrogated on (b)(6) 2017and reported episode of convulsions and when paramedics arrived the patient had low blood pressure.The patient stopped utilizing the ptm, as they were fearful the issue may reoccur.The next day, the patient reported increased black out episodes and the pump was refilled without clonidine.It was indicated the event was related to the device or therapy and related to the drug bupivacaine/clonidine and the drug action being increase dose.The issue resolved without sequelae on (b)(6) 2017.
|